Pharmacosmos Holding A/S
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
6
Ending by 2030
Mar 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for Synthesis of 1,4-Diazaspiro[5.5]UNDECAN-3-ONE (US 11,708,337) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 3 fees due Feb 8 to 13, 2027 · next Feb 8
- 2 fees due Mar 17, 2027
- 1 fee due Apr 8, 2027The maintenance fee for Hspc-Sparing Treatments for Rb-Positive Abnormal Cellular Proliferation (US 10,434,104) comes due Apr 8, 2027. Unpaid by Oct 8, 2027, it lapses early.
- 2 fees due May 5 to 7, 2027 · next May 5
- 1 fee due Jun 26, 2027The maintenance fee for Stable iron oligosaccharide compound (US 11,851,504) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
- 1 fee due Aug 16, 2027The maintenance fee for Lactam Kinase Inhibitors (US 9,260,442) comes due Aug 16, 2027. Unpaid by Feb 16, 2028, it lapses early.
- 1 fee due Oct 14, 2027The maintenance fee for Pyrimidine-Based Compounds for the Treatment of Cancer (US 10,618,905) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.
- 1 fee due Nov 19, 2027The maintenance fee for Antiproliferative Pyrimidine-Based Compounds (US 10,654,831) comes due Nov 19, 2027. Unpaid by May 19, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,414,831 | Stable Iron Oligosaccharide Compound In force · Medium confidence | In force | Medium confidence | |
| US 10,865,255 | Stable Iron Oligosaccharide Compound In force · High confidence | In force | High confidence | |
| US 12,030,962 | Stable Iron Oligosaccharide Compound In force · High confidence | In force | High confidence | |
| US 9,439,969 | Stable Iron Oligosaccharide Compound In force · High confidence | In force | High confidence | |
| US 11,851,504 | Stable iron oligosaccharide compound In force · USPTO record | In force | USPTO record | |
| US 8,815,301 | Stable Iron Oligosaccharide Compound In force · High confidence | In force | High confidence | |
| US 8,598,197 | CDK Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 8,691,830 | CDK Inhibitors In force · High confidence | In force | High confidence | |
| US 8,822,683 | CDK Inhibitors In force · High confidence | In force | High confidence | |
| US 8,829,012 | CDK Inhibitors In force · High confidence | In force | High confidence |
Also on record, not counted in the 78: 6 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 2 abandoned · 3 no status recorded